The Role of Autonomic Dysregulation from Pathophysiology to Therapeutics of Multiple Sclerosis: A Putative Novel Treatment Target?

Autonomic Nervous System (ANS) dysfunction (AuD) is a common cause of disability in people living with Multiple Sclerosis (MS), but clinical manifestations are heterogeneous and therapeutic options are lacking.AuD is implicated as having a possible role in the regulation of inflammation and neurodegeneration.Hence, treatments with drugs that affect the ANS may have an impact in the inflammatory and neurodegenerative processes intrinsic to MS, resulting in an intriguing and potentially significant novel therapeutic consideration.Additionally, just alike patients with most other chronic diseases, MS patients often are exposed to a broad range of treatments both disease-specific and due to complications or co-morbidities.Considering them into an integrated context affords the opportunity to understand and exploit their therapeutic potential.